NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount of 6.125% notes due May 1, 2038 in an underwritten public offering.
Banc of America Securities LLC, J.P. Morgan Securities Inc., and Morgan Stanley are acting as representatives of the underwriters.
Bristol-Myers Squibb intends to use the net proceeds from the offering to finance the repayment of its $400 million principal amount of the 4.00% Notes due August 2008, to finance redemptions of its $1.2 billion principal amount of Floating Rate Convertible Debentures due 2023 at the option of holders in 2008 and general corporate purposes. The offering is expected to close on May 1, 2008.
The prospectus supplement and accompanying prospectus related to the offering of the notes may be obtained by contacting one of the following representatives: Banc of America Securities, LLC
Capital Markets Operations
100 West 33rd Street, 3rd Floor
New York, NY 10001
Telephone: 800-294-1322 J.P. Morgan Securities Inc. 270 Park Avenue, 8th Floor
New York, NY 10017
Telephone: 212-834-4533 Morgan Stanley and Company, Inc. 180 Varick Street 2/F
New York, NY 10014
Attention: Prospectus Department
Telephone: 866-718-1649
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb's business, including those identified in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2007, particularly under "Item 1A. Risk Factors". Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life. DATASOURCE: Bristol-Myers Squibb Company CONTACT: Media: Brian Henry, Communications, +1-609-252-3337, ; Investors: John Elicker, Investor Relations, +1-212-546-3775, Web site: http://www.bms.com/
|